TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis
Public ClinicalTrials.gov record NCT00023335. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
TBTC Study 22: Efficacy and Safety of Once-Weekly Rifapentine and Isoniazid Compared to Efficacy and Safety of Once-Weekly Rifapentine and Isoniazid Compared to Twice-Weekly Rifampin and Isoniazid in the Continuation Phase of Therapy for Pulmonary Tuberculosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary Objective: To compare, at the completion of the follow-up phase, the clinical and bacteriologic relapse rates associated with the two study regimens. Secondary Objectives: To compare the clinical and bacteriologic failure rates of the two study regimens at the completion of the study phase therapy. To compare the clinical and bacteriologic response rates for the two study regimens among patients who began study phase therapy with signs and symptoms of tuberculosis or cultures positive for M. tuberculosis. To compare the toxicity associated with the two study regimens by comparing discontinuation rates due to adverse events and occurrence rates of signs and symptoms associated with adverse events during study phase therapy. To compare mortality rates of the two study regimens. To compare the rates of completion of therapy within 22 weeks for the two study regimens. To compare the rate of development of drug-resistant tuberculosis in the two study regimens among study patients classified as treatment failures or relapses. To compare all of the above performance characteristics for the two study regimens in a small subset of HIV seropositive patients. To compare attitudes and beliefs about participation in this study between patients who complete study therapy and those who fail to complete study therapy.
Study identification
- NCT ID
- NCT00023335
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,000 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 1995 (Type not available)
- Primary completion
- Not listed
- Completion
- Mar 2001 (Type not available)
- Last update posted
- Sep 5, 2005
1995 – 2001
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Central Arkansas Veterans Health System | Little Rock | Arkansas | 72205 | — |
| LA County/USC Medical Center | Los Angeles | California | 90033 | — |
| University of California, San Francisco | San Francisco | California | 94110 | — |
| Denver Department of Public Health and Hospitals | Denver | Colorado | 80204 | — |
| Washington, D.C. VAMC | Washington D.C. | District of Columbia | 20422 | — |
| Chicago VA Medical Center (Lakeside) | Chicago | Illinois | 60611 | — |
| Hines VA Medical Center | Hines | Illinois | 60141 | — |
| Johns Hopkins University School of Medicine | Baltimore | Maryland | 21287-0003 | — |
| Boston Medical Center | Boston | Massachusetts | 02118 | — |
| New Jersey Medical School | Newark | New Jersey | 07107-3001 | — |
| New York University School of Medicine | New York | New York | 10016 | — |
| Columbia University/Presbyterian Medical Center | New York | New York | 10032 | — |
| Harlem Hospital Center | New York | New York | 10037 | — |
| Carolinas Medical Center | Charlotte | North Carolina | 28203 | — |
| Duke University Medical Center | Durham | North Carolina | 34222 | — |
| Nashville VA Medical Center | Nashville | Tennessee | 37212-2637 | — |
| University of North Texas Health Science Center | Fort Worth | Texas | 76107-2699 | — |
| Thomas Street Clinic | Houston | Texas | 77009 | — |
| Audi L. Murphy VA Hospital | San Antonio | Texas | 78284 | — |
| Seattle King County Health Department | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00023335, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 5, 2005 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00023335 live on ClinicalTrials.gov.